HOXA11 and neoplasm: We observed that, after silencing HOXA11-AS1 or treatment with PBMCs, the pathological degree and proliferation of the tumor and the expressions of PD-L1 and Ki-67 were reduced, while these effects were further enhanced by the knockdown of HOXA11-AS1 and the addition of PBMCs together (Figure 6A,B), indicating the effective anti-tumor role of HOXA11-AS1 deletion in vivo.